Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531)
in the treatment of thrombocytopenia in pediatric subjects with chronic ITP. We will also
evaluate the efficacy of romiplostim (AMG 531) and characterize the pharmacokinetics of
romiplostim (AMG 531). It is anticipated that romiplostim (AMG 531), when given at an
effective dose and schedule, will be well tolerated treatment for thrombocytopenia among
pediatric subjects with chronic ITP.